AstraZeneca's Lynparza meets main goal of late-stage cancer study
British drugmaker AstraZeneca Plc said on Tuesday its cancer drug being jointly developed with U.S.-based Merck& Co met the primary goal in a late-stage study for pancreatic cancer.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: AstraZeneca | Cancer | Cancer & Oncology | Health | Merck | Pancreas | Pancreatic Cancer | Study | UK Health